Biomarker Assessment in Parkinson’s Disease Dementia and Dementia with Lewy Bodies by the Immunomagnetic Reduction Assay and Clinical Measures

Written By Yiran Gan
Biomarker Assessment in Parkinson's Disease Dementia and Dementia with Lewy Bodies by the Immunomagnetic Reduction Assay and Clinical Measures - Malaty et al. 2024

Biomarker Assessment in Parkinson's Disease Dementia and Dementia with Lewy Bodies by the Immunomagnetic Reduction Assay and Clinical Measures

Authors: Giovanni R. Malaty, Boris Decourt, Holly A. Shill, Marwan N. Sabbagh

Journal: Journal of Alzheimer's Disease Reports 8 (2024) 1361–1371

© 2024 Malaty, Decourt, Shill and Sabbagh

Journal of Alzheimer's Disease Reports - IOS Press

Yiran Gan
Previous

Theoretical Explorations of Reductions in The Alternative-current Magnetic Susceptibility of Reagent in Immunomagnetic Reduction Assay
Next

Longitudinal assessment of plasma biomarkers for early detection of cognitive changes in subjective cognitive decline